Associate Professor of Medicine
University of Iowa
I am GU medical oncologist, my clinical and translational research has been geared towards experimental therapeutics in renal and bladder cancers. I serve as the Director for our Phase 1 Program at the Holden Comprehensive Cancer Center. Being at an NCI-designated Comprehensive Cancer Center offers me the resources to be on the cutting edge of cancer science and provides a unique opportunity to treat my patients on clinical trials at different phases. My main research project has been investigating high-dose selenium in metastatic renal cancer. We presented the preliminary results at the American Urology Association 2020 Annual Meeting and Kidney Cancer Research Summit 2021. I also helped designing a multi-center trial and protocol for a phase 1/2 clinical trial combining indoximod “an IDO inhibitor” with checkpoint inhibitors in metastatic melanoma patients. I presented the preliminary results of this trial at the American Association of Cancer Research (AACR) Annual Meeting Plenary Session in Washington, D.C, April 2017. Results are published in JITC 2021. I am institutional PI for multiple clinical trials sponsored by industry or cooperative groups.